Analystreport

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $91

Reata Pharmaceuticals, Inc. - Class A  (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com